Telitacicept clinical trials
Also written RC18.
How each study uses telitacicept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the telitacicept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2023 (13)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 7 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 30
RemeGen Co., Ltd. (19) · Vor Biopharma (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Chinese SLE Treatment And Research Group (3) · Renmin Hospital of Wuhan University (2) · Ruijin Hospital (2) · The Children's Hospital of Zhejiang University School of Medicine (2) · First Affiliated Hospital of Wenzhou Medical University (2)
Often tested with
Tested in the same studies.
Daratumumab (1) · IBI3034 (1) · Efgartigimod alfa (1) · Cyclophosphamide (1) · Belimumab (1) · Mycophenolic Acid (1) · Interleukin-2 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 12, 4 in phase 3
Studies that test telitacicept, phase 3 first.
- Dec 2026TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)Phase 2/3 · Zhongming Qiu
- Dec 2026A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)Phase 3 · RemeGen Co., Ltd.
- Mar 2027A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Phase 3 · Vor Biopharma
- Jun 2027Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis NephritisPhase 3 · Guixia Ding
- Dec 2026Efficacy and Safety of Telitacicept in IgANNot applicable · Ruijin Hospital
- Dec 2026Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)Phase 4 · Chinese SLE Treatment And Research Group
- Jan 2027Efficacy and Safety of Telitacicept in the Treatment of Systemic SclerosisPhase 2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Jan 2027IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyPhase 1 · Innovent Biologics (Suzhou) Co. Ltd.
- May 2027Telitacicept for PGNMID: A Single-Arm StudyPhase 2 · Peking University First Hospital
- Jun 2027The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentPhase 2 · Nanjing University School of Medicine
Studies
Open first, then newest update. How each study uses telitacicept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 54
- IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07886476Written as Telitacicept
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseRecruitingPhase 3Vor BiopharmaNCT07404865Written as Telitacicept
- Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisRecruitingPhase 2Peking University People's HospitalNCT07796516Written as Telitacicept 160mg
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseaseNot yet recruitingPhase 3RemeGen Co., Ltd.NCT07495033Written as Telitacicept
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingPhase 3RemeGen Co., Ltd.NCT07249632Written as Telitacicept
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingPhase 2Nanjing University School of MedicineNCT07340463Written as Telitacicept
- A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNot applicableThe Children's Hospital of Zhejiang University School of MedicineNCT07298928Written as Telitacicept
- TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)Not yet recruitingPhase 2/3Zhongming QiuNCT07355257Written as Telitacicept 240mg
- Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis NephritisNot yet recruitingPhase 3Guixia DingNCT07052981Written as Telitacicept
- Telitacicept for the Treatment of Refractory RANot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07008196Written as Telitacicept
- Telitacicept for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaRecruitingPhase 2Beijing HospitalNCT05998759Written as Telitacicept
- Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia GravisNot yet recruitingNot applicableFirst Affiliated Hospital of Wenzhou Medical UniversityNCT06827587Written as Efgartigimod + Telitacicept (1-week interval) group
- Efficacy and Safety of Telitacicept in the Treatment of Systemic SclerosisRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06375005Written as Telitacicept
- Efficacy and Safety of Telitacicept in IgANRecruitingNot applicableRuijin HospitalNCT06654596Written as Telitacicept 240mg
- Telitacicept and Low-dose Steroids in Refractory Myasthenia GravisNot yet recruitingPhase 4First Affiliated Hospital of Wenzhou Medical UniversityNCT06723548Written as Telitacicept
- The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous NephropathyNot yet recruitingPhase 2Renmin Hospital of Wuhan UniversityNCT06614985Written as Telitacicept
- A Study of Telitacicept in Lupus NephritisRecruitingPhase 2RemeGen Co., Ltd.NCT05680480Written as Telitacicept 240 mg
- Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic SyndromeRecruitingPhase 3The Children's Hospital of Zhejiang University School of MedicineNCT06125405Written as Telitacicept
- The Safety and Efficacy of Telitacicept in the Treatment of Systemic SclerosisRecruitingPhase 4Peking University Third HospitalNCT06546540Written as Telitacicept
- Efficacy and Safety of Telitacicept for Prevention of Flares in SLE PatientsRecruitingNot applicableRenJi HospitalNCT06394063Written as Telitacicept
See all 54 studies that test telitacicept →
Given beside what is tested · 1 — telitacicept is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call telitacicept · ClinicalTrials.gg INT001851
- MeSH (NLM) C000722462telitaciceptOne source ClinicalTrials.gov
- UNII (FDA) 1FHM3D7Z49TELITACICEPTOne source FDA
- NCI Thesaurus C166498TelitaciceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722462 | telitacicept | One source ClinicalTrials.gov |
| UNII (FDA) | 1FHM3D7Z49 | TELITACICEPT | One source FDA |
| NCI Thesaurus | C166498 | Telitacicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.